-
公开(公告)号：US20240399372A1
公开(公告)日：2024-12-05
申请号：US18806002
申请日：2024-08-15
Applicant: Pfizer Inc.
Inventor： Debkishore Mitra , Frank B. Myers III , John Robert Waldeisen , Ivan Krastev Dimov
IPC: B01L3/00 , C12Q1/6844 , G01N27/447
Abstract: Systems and methods for performing biological assays are provided herein. The systems and methods determine one or more characteristics of a nucleic acid amplification sample based on a modified optical property of the sample.
-
公开(公告)号：US20240299941A1
公开(公告)日：2024-09-12
申请号：US18652012
申请日：2024-05-01
Applicant: Pfizer Inc.
Inventor： Debkishore Mitra , Frank B. Myers III , John Robert Waldeisen , Ivan Krastev Dimov
CPC classification number: B01L3/502738 , A61J1/14 , B01L7/52 , G01J3/524 , B01L2200/141 , B01L2300/048 , B01L2300/049 , B01L2300/0864 , B01L2300/1822 , B01L2300/1827 , B01L2400/049 , B01L2400/0694
Abstract: Selectively vented biological assay devices and methods of performing biological assays with such devices are provided herein. Disclosed devices include a selective venting clement having passively tunable porosity. The methods include controlling fluid flow within the subject devices with the selective venting element.
-
公开(公告)号：US12023665B2
公开(公告)日：2024-07-02
申请号：US16081800
申请日：2017-03-14
Applicant: Pfizer Inc.
Inventor： Frank B. Myers, III , Debkishore Mitra , John Robert Waldeisen , Ivan Krastev Dimov
CPC classification number: B01L3/502715 , B01L7/52 , G01N21/0332 , G01N21/78 , G01N33/50 , B01L2200/12 , B01L2300/041 , B01L2300/0627 , B01L2300/123 , B01L2300/168 , B01L2300/1822 , B01L2300/1827 , B01L2300/1877 , G01N2021/0346 , G01N2021/786 , G01N21/80 , G01N2201/0221
Abstract: Devices and methods for modifying optical properties of biological samples or aspects thereof are provided. The subject methods include generating a reaction product with a device and reacting the reaction product to sufficiently modify an optical property to allow detection of the modified optical property.
-
公开(公告)号：US11954851B2
公开(公告)日：2024-04-09
申请号：US17364773
申请日：2021-06-30
Applicant: Pfizer Inc.
Inventor： Ivan Krastev Dimov , Frank B. Myers, III , John Robert Waldeisen , Debkishore Mitra
IPC: G06T7/00 , A61B5/00 , A61B5/103 , G06T7/60 , G06T7/90 , G16B40/00 , G16H10/40 , G16H30/40 , G16H50/20
CPC classification number: G06T7/0012 , A61B5/0059 , A61B5/1032 , A61B5/6898 , A61B5/7282 , A61B5/742 , G06T7/60 , G06T7/90 , G06T7/97 , G16B40/00 , G16H10/40 , G16H30/40 , G16H50/20 , A61B2576/00
Abstract: A diagnostic system performs disease diagnostic tests using at least an optical property modifying device and a mobile device. A user provides a biological sample from a patient to the optical property modifying device that reacts with a reagent in one or more reaction chambers of the device. The user captures one or more images of the one or more reaction chambers using an optical sensor of the mobile device. The diagnostic system can determine a quality level of the images based on factors such as skew, scale, focusing, shadowing, or white-balancing. Based on an analysis of the captured image, the diagnostic system can determine a test result of a disease diagnostic test for the patient. The diagnostic system may communicate the test result, as well as instructions for the disease diagnostic test, to the user via the mobile device.
-
Patent Agency Ranking
公开(公告)号：US12090482B2
公开(公告)日：2024-09-17
申请号：US17342533
申请日：2021-06-08
Applicant: Pfizer Inc.
Inventor： Debkishore Mitra , Frank B. Myers, III , John Robert Waldeisen , Ivan Krastev Dimov
IPC: B01L3/00 , C12Q1/6844 , G01N27/447
CPC classification number: B01L3/5029 , C12Q1/6844 , G01N27/447 , B01L2300/0627 , B01L2300/0672 , B01L2300/0681 , B01L2300/0832 , B01L2300/0867 , B01L2300/087 , B01L2300/14 , B01L2300/1822 , B01L2300/1827 , B01L2300/1877 , B01L2400/0478 , B01L2400/0487 , B01L2400/0683 , B01L2400/0694 , C12Q1/6844 , C12Q2531/119 , C12Q2563/113 , C12Q2565/629 , C12Q1/6844 , C12Q2531/113 , C12Q2563/113 , C12Q2565/629
Abstract: Systems and methods for performing biological assays are provided herein. The systems and methods determine one or more characteristics of a nucleic acid amplification sample based on a modified optical property of the sample. The nucleic acid amplification sample is reacted with an optical property modifying reagent in a reaction chamber of within a sample preparation device.
-
公开(公告)号：US20240269672A1
公开(公告)日：2024-08-15
申请号：US18636030
申请日：2024-04-15
Applicant: Pfizer Inc.
Inventor： Frank B. Myers, III , Debkishore Mitra , John Robert Waldeisen , Ivan Krastev Dimov
CPC classification number: B01L3/502715 , B01L7/52 , G01N21/0332 , G01N21/78 , G01N33/50 , B01L2200/12 , B01L2300/041 , B01L2300/0627 , B01L2300/123 , B01L2300/168 , B01L2300/1822 , B01L2300/1827 , B01L2300/1877 , G01N2021/0346 , G01N2021/786 , G01N21/80 , G01N2201/0221
Abstract: Devices and methods for modifying optical properties of biological samples or aspects thereof are provided. The subject methods include generating a reaction product with a device and reacting the reaction product to sufficiently modify an optical property to allow detection of the modified optical property.
-
公开(公告)号：US12023671B2
公开(公告)日：2024-07-02
申请号：US17677999
申请日：2022-02-22
Applicant: Pfizer Inc.
Inventor： Debkishore Mitra , Frank B. Myers, III , John Robert Waldeisen , Ivan Krastev Dimov
CPC classification number: B01L3/502738 , A61J1/14 , B01L7/52 , G01J3/524 , B01L2200/141 , B01L2300/048 , B01L2300/049 , B01L2300/0864 , B01L2300/1822 , B01L2300/1827 , B01L2400/049 , B01L2400/0694
Abstract: Selectively vented biological assay devices and methods of performing biological assays with such devices are provided herein. Disclosed devices include a selective venting element having passively tunable porosity. The methods include controlling fluid flow within the subject devices with the selective venting element.
-
公开(公告)号：US20240132944A1
公开(公告)日：2024-04-25
申请号：US18111791
申请日：2023-02-20
Applicant: Pfizer Inc.
Inventor： Debkishore Mitra , Ivan Krastev Dimov , John Robert Waldeisen
IPC: C12Q1/6844
CPC classification number: C12Q1/6844 , C12Q1/6846
Abstract: Colorimetry is used to detect amplification reaction products. A sample is contacted with a reaction mix under conditions such that an amplification reaction occurs and produces an amplification reaction product if the sample contains a target nucleic acid template molecule. The reaction mix includes an enzyme for catalyzing the amplification reaction, and at least one halochromic agent. If the target nucleic acid template molecule is present, the amplification reaction changes the starting pH of the reaction mix to cause a detectable colorimetric change of the halochromic agent, thereby indicating the presence of the target nucleic acid. If the target nucleic acid template molecule is not present, the amplification reaction does not generate an adequate number of protons to sufficiently change the starting pH of the reaction mix to cause a detectable colorimetric change of the halochromic agent, thereby indicating that the amplification reaction product has not been produced.
-
公开(公告)号：US20240020836A1
公开(公告)日：2024-01-18
申请号：US18364401
申请日：2023-08-02
Applicant: Pfizer Inc
Inventor： Ivan Krastev Dimov , Frank B. Myers, III , John Robert Waldeisen , Debkishore Mitra
IPC: G06T7/00 , A61B5/00 , G06T7/60 , G06T7/90 , G16B40/00 , A61B5/103 , G16H50/20 , G16H10/40 , G16H30/40
CPC classification number: G06T7/0012 , G06T7/97 , A61B5/6898 , G06T7/60 , G06T7/90 , G16B40/00 , A61B5/1032 , G16H50/20 , A61B5/0059 , G16H10/40 , G16H30/40 , A61B5/7282 , A61B5/742 , A61B2576/00
Abstract: A diagnostic system performs disease diagnostic tests using at least an optical property modifying device and a mobile device. A user provides a biological sample from a patient to the optical property modifying device that reacts with a reagent in one or more reaction chambers of the device. The user captures one or more images of the one or more reaction chambers using an optical sensor of the mobile device. The diagnostic system can determine a quality level of the images based on factors such as skew, scale, focusing, shadowing, or white-balancing. Based on an analysis of the captured image, the diagnostic system can determine a test result of a disease diagnostic test for the patient. The diagnostic system may communicate the test result, as well as instructions for the disease diagnostic test, to the user via the mobile device.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.017 seconds)
